---
id: 247
title: Aspergillus Species
category: organisms
subcategory: fungi
tags: [Aspergillus, aspergillosis, voriconazole, ABPA, invasive-aspergillosis, galactomannan]
difficulty: high
---

## Question

What are key clinical syndromes and treatment considerations for *Aspergillus*? Use **"Invasive: Voriconazole, ABPA: Steroids + Itraconazole, Neutropenia High-Risk"** framework.

## Answer

### **Species:**

***A. fumigatus*** (90% of invasive aspergillosis)
***A. flavus, A. niger, A. terreus***

### **Key Clinical Syndromes:**

**Invasive Pulmonary Aspergillosis (IPA):**
- **Neutropenia, transplant, steroids** (immunocompromised)
- **Angioinvasive** (vascular invasion → thrombosis, hemorrhage, infarction)
- **High mortality** (30-90% if untreated)
- **CT:** Halo sign (early), air-crescent sign (late recovery)

**Chronic Pulmonary Aspergillosis:**
- **Cavitary disease** (pre-existing lung disease: TB, COPD, sarcoidosis)
- **Aspergilloma** (fungus ball in cavity)
- **Chronic necrotizing** (semi-invasive, slow progression)

**Allergic Bronchopulmonary Aspergillosis (ABPA):**
- **Asthma, cystic fibrosis**
- **Hypersensitivity reaction** (not invasive infection)
- **Eosinophilia, ↑IgE, central bronchiectasis**

**Aspergillus Tracheobronchitis:**
- **Lung transplant, airway anastomosis**
- **Pseudomembranous, ulcerative**

**Chronic Necrotizing Aspergillosis (CPA):**
- **Slowly progressive cavitation** (months to years)
- **Mildly immunocompromised** (COPD, diabetes, alcohol)

**Disseminated Aspergillosis:**
- **CNS** (brain abscess, meningitis)
- **Endocarditis** (prosthetic valves, cardiac surgery)
- **Osteomyelitis** (vertebral, post-surgery)
- **Cutaneous** (disseminated or primary in burns)

### **Diagnosis:**

**Invasive Aspergillosis:**

**Imaging (CT Chest):**
- **Halo sign** (ground-glass opacity surrounding nodule) - early, suggestive
- **Air-crescent sign** (crescent of air around necrotic tissue) - late, during neutrophil recovery
- **Nodules, consolidation, cavitation**

**Galactomannan:**
- **Serum galactomannan** (≥0.5 optical density index suggests invasive)
- **BAL galactomannan** (≥1.0 suggests invasive)
- **Serial monitoring** (trend important)
- **False positives:** Piperacillin-tazobactam, some foods

**β-D-Glucan:**
- **Elevated** (but non-specific, any invasive fungal infection)

**Culture:**
- **BAL, lung biopsy** (definitive, but insensitive)
- **Blood cultures negative** (rarely grows in blood)

**Histopathology:**
- **Septate hyphae, acute-angle branching** (45°)
- **Tissue invasion, angioinvasion**

**ABPA:**
- **↑Total IgE** (>1000 IU/mL)
- **↑*Aspergillus*-specific IgE, IgG**
- **Peripheral eosinophilia** (>500 cells/μL)
- **Central bronchiectasis** (imaging)

### **Treatment:**

**Invasive Pulmonary Aspergillosis:**

**First-Line:**
- **Voriconazole 6 mg/kg IV q12h × 2 doses → 4 mg/kg IV q12h**
  - **Then switch to PO:** 200-300mg PO BID
  - **Monitor levels** (trough 1-5.5 mcg/mL, drug interactions, hepatotoxicity)

**Alternative:**
- **Isavuconazole 372mg PO/IV q8h × 6 doses (loading) → 372mg daily**
- **Liposomal amphotericin B 3-5 mg/kg IV daily** (if azole intolerance/resistance)
- **Posaconazole 300mg PO BID day 1 → 300mg daily** (salvage or prophylaxis)

**Combination Therapy:**
- **Voriconazole + echinocandin** (micafungin, caspofungin) - consider if severe, refractory
- **Data limited** (not routinely recommended)

**Duration:**
- **Minimum 6-12 weeks** (often months)
- **Until resolution of lesions + immunosuppression resolves**

**Salvage (Refractory):**
- **Posaconazole 300mg PO daily**
- **Liposomal amphotericin B**
- **Echinocandin + azole combination**

**Surgical Resection:**
- **Consider if:** Hemoptysis (aspergilloma), lesion near great vessels, refractory to antifungals

**ABPA:**
- **Prednisone 0.5 mg/kg PO daily × 2 weeks → taper over 3-6 months**
- **+ Itraconazole 200mg PO BID × 16 weeks** (reduces steroid requirement, prevents relapses)
- **Monitor IgE** (goal: decrease by 25-50%)

**Aspergilloma (Fungus Ball):**
- **Observation** if asymptomatic
- **Surgical resection** if hemoptysis (can be life-threatening)
- **Intracavitary amphotericin B** (rarely used)
- **Oral azoles NOT effective** (poor penetration into cavity)

**Chronic Pulmonary Aspergillosis:**
- **Itraconazole 200mg PO BID** OR **voriconazole 200mg PO BID × 6-12 months** (or longer)

**Aspergillus Endocarditis:**
- **Voriconazole** + **surgical valve replacement** (medical therapy alone insufficient)
- **Duration:** ≥6 weeks post-surgery (often lifelong suppression)

**CNS Aspergillosis:**
- **Voriconazole** (good CNS penetration)
- **Consider surgical drainage** if abscess

### **Prophylaxis:**

**High-Risk Patients:**
- **Acute leukemia** (induction chemotherapy)
- **Allogeneic HSCT** (graft-vs-host disease on immunosuppression)
- **Lung transplant**

**Agents:**
- **Posaconazole 300mg PO daily** (preferred)
- **Voriconazole 200mg PO BID**
- **Micafungin 50mg IV daily** (alternative)

### **Antifungal Resistance:**

**Azole Resistance:**
- **Emerging** (environmental exposure to azole fungicides)
- **Mutations:** *cyp51A* gene
- **Consider if:** Prior azole exposure, endemic areas (Netherlands, India)

### **Special Populations:**

**Neutropenic Patients:**
- **Highest risk** (acute leukemia, HSCT)
- **Early aggressive therapy** (voriconazole)
- **G-CSF** if severe neutropenia

**Lung Transplant:**
- **Anastomotic infection** (tracheobronchitis)
- **Prophylaxis:** Inhaled amphotericin B, systemic azoles

**Cystic Fibrosis:**
- **ABPA common** (10-15% of CF patients)
- **Colonization frequent** (not always pathogenic)

## Key Points

### **Invasive Aspergillosis = Voriconazole:**
- **6 mg/kg IV q12h × 2 → 4 mg/kg IV q12h** (then PO 200-300mg BID)
- **Monitor levels** (trough 1-5.5 mcg/mL)

### **Neutropenia = Highest Risk:**
- **Acute leukemia, HSCT**
- **Angioinvasive, high mortality**

### **ABPA = Steroids + Itraconazole:**
- **Prednisone taper + itraconazole 200mg BID × 16 weeks**
- **Asthma, CF patients**

### **CT Findings:**
- **Halo sign** (early, ground-glass opacity)
- **Air-crescent sign** (late, neutrophil recovery)

### **Aspergilloma = Surgical Resection if Hemoptysis:**
- **Fungus ball in cavity**
- **Oral azoles NOT effective**

### **Clinical Pearls:**
- **Invasive:** Voriconazole 6 mg/kg IV q12h × 2 → 4 mg/kg IV q12h (monitor levels)
- **Neutropenia:** Highest risk (angioinvasive, high mortality)
- **ABPA:** Prednisone taper + itraconazole 200mg BID × 16 weeks
- **Halo sign** (early), **air-crescent sign** (late)
- **Aspergilloma:** Resect if hemoptysis (azoles NOT effective)
- **Duration:** 6-12 weeks minimum (often months until immune reconstitution)

## Sources

- [IDSA: Aspergillosis Guidelines 2024]
- [CID: Invasive Aspergillosis Management 2024]

## Media

N/A
